Status:
RECRUITING
Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy
Lead Sponsor:
Shengjing Hospital
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
NA
Brief Summary
For patients with early breast cancer with negative axillary lymph nodes, sentinel lymph node biopsy (SLNB) can largely avoid complications such as upper limb lymphoedema caused by axillary lymph node...
Detailed Description
A total of 100 patients who are first diagnosed with breast cancer (stage N2 or N3) at the Liaoning Oncology Hospital will be recruited. Inclusive criteria: 1) Invasive breast cancer confirmed by biop...
Eligibility Criteria
Inclusion
- invasive breast cancer confirmed by biopsy and histology;
- based on prone CT scan and Doppler ultrasound, axillary stage cN2-3;
- agree and meet the requirements for NAC;
- meet surgical requirements and agree to undergo surgery after NAC;
- the regime of NAC follows the NCCN recommendations.
Exclusion
- • previous history of breast cancer or other malignant tumors.
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05241119
Start Date
November 1 2021
End Date
October 31 2028
Last Update
February 15 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China, 110042
2
Jianyi Li
Shenyang, Liaoning, China, 110042